Similarly, several reviews have revealed the associations of high levels of lipocalin 2 with poor prognosis in ER − /PR − /HER2 + tumors, and ER- and PR-negative status in tumor samples from patients with breast cancer [11, 12], which is consistent with our study. This evidence concerns the gene LCN2 and breast carcinoma.